ABVC BioPharma, Inc. (ABVC)
NASDAQ: ABVC · Real-Time Price · USD
1.070
-0.010 (-0.93%)
At close: Apr 28, 2026, 4:00 PM EDT
1.070
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT
ABVC BioPharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
19
Market Cap
26.44M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 509.59K | 357.16K | 234.31% |
| Dec 31, 2023 | 152.43K | -817.35K | -84.28% |
| Dec 31, 2022 | 969.78K | 613.99K | 172.57% |
| Dec 31, 2021 | 355.80K | -127.25K | -26.34% |
| Dec 31, 2020 | 483.05K | -218.67K | -31.16% |
| Dec 31, 2019 | 701.72K | 694.76K | 9,987.97% |
| Dec 31, 2018 | 6.96K | - | - |
| Dec 31, 2017 | - | - | - |
| Sep 30, 2017 | - | - | - |
| Dec 31, 2016 | 988.15K | - | - |
| Sep 30, 2016 | - | - | - |
| Dec 31, 2015 | 0 | - | - |
| Sep 30, 2015 | 3.36K | -4.43K | -56.85% |
| Sep 30, 2013 | 7.79K | 2.07K | 36.28% |
| Sep 30, 2012 | 5.71K | 2.52K | 79.12% |
| Sep 30, 2011 | 3.19K | -11.67K | -78.53% |
| Sep 30, 2010 | 14.86K | - | - |
| Sep 30, 2009 | - | - | - |
| Sep 30, 2008 | 25.09K | -16.58K | -39.78% |
| Sep 30, 2007 | 41.67K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionABVC News
- 1 year ago - ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners - GlobeNewsWire
- 1 year ago - ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners - GlobeNewsWire
- 1 year ago - ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements - GlobeNewsWire
- 2 years ago - AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share - GlobeNewsWire
- 2 years ago - ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M - GlobeNewsWire
- 2 years ago - ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M - GlobeNewsWire
- 2 years ago - ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M - GlobeNewsWire
- 2 years ago - ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine - GlobeNewsWire